| Today's Big NewsApr 19, 2023 |
|
An ideal home for reshoring. U.S. manufacturers gain greater control of and visibility into their supply chains, as well as access to a robust STEM talent pool, by setting up operations in Puerto Rico. 
|
|
| By Angus Liu J&J and Legend's CAR-T therapy Carvykti slashed the risk of disease progression or death by a whopping 74% in multiple myeloma, according to a leaked abstract Fierce Pharma has obtained. The number exceeds analysts' expectations and puts Bristol Myers Squibb on notice. |
|
|
|
By Andrea Park True to its namesake, Intuitive Surgical’s da Vinci robotic surgery system has become increasingly prolific amid the current renaissance period—as in, the resurgence of regular healthcare procedures as the COVID-19 pandemic transitions into an endemic. |
By James Waldron If there’s a slowdown in VC investment, no one’s told Forbion. The European life sciences-focused growth fund has raised 1.35 billion euros ($1.5 billion) across two funds, marking the firm’s largest fundraising to date. |
By Fraiser Kansteiner Represented by Unite, the UK’s biggest labor union, 750 GSK staffers have voted to strike after the company offered a 6% pay raise with a one-off lump sum of £1,300—an amount Unite says is “significantly below” the rate of inflation. GSK’s offer to its employees represents a “substantial real terms pay cut” in light of the U.K.'s true inflation rate of 13.5%, Unite said in a press release. |
|
Tuesday, May 23, 2023 | 2pm ET / 11am PT Clinical trials are complex, time-consuming, and costly. But what if you could use simulation to guide your decisions and optimize your trial design? In this webinar, we'll discuss the power of simulation-guided trial design (SGTD) and explain its benefits to clinical development strategies. Register now to join us. 
|
|
By Andrea Park With COVID-related sales expected to clock in at a mere fraction of last year’s—and to drag down 2023’s total sales in the process—Abbott is redoubling its focus on non-COVID-related operations across the company. |
By Kevin Dunleavy It appears that Seagen’s David Epstein will have quite a short tenure as CEO of the cancer specialist. But it’s going to pay off nicely. Epstein, who was hired in November by the Seattle biotech and helped execute its $43 billion sale last month to Pfizer, collected $57.5 million in total pay last year, according to an SEC filing. |
By Nick Paul Taylor Revolo Biotherapeutics thinks it has the data to keep advancing a would-be challenger to Dupixent. In a small, short phase 2a allergy trial, the biotech linked its peptide to a “numeric reduction” on the primary endpoint, emboldening it to start looking forward to further development. |
By Zoey Becker The agency pulled its emergency use authorizations for the original COVID-19 vaccines and now says most people need only one dose of the updated shots. |
By Conor Hale Just weeks after securing an FDA clearance for its robotic lung surgery system, Noah Medical has been flooded with venture capital dollars, led by Softbank Vision Fund. |
By Nick Paul Taylor The Metrodora Institute has opened the doors of its medical and research center in Salt Lake City, giving biopharma companies a new neuroimmune drug development and clinical trial partner in Utah. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about biotech’s top money raisers in 2022. We also cover J&J's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines. |
|
|---|
|
|
|
Wednesday, April 26, 2023 | 12pm ET / 9am PT Our speakers will explore how science-based organizations are producing more data than ever before, and why digital transformation strategies to leverage this data, like AI and machine learning, require the right infrastructure of connected, searchable, and harmonized data. Register now. |
|
Research Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
Whitepaper This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
